Open AccessJournal Article
Screening for breast cancer in England: past and future
Valerie Beral,S. Cush,Ian O. Ellis,J Emery,K Faulkner,Rosalind M. Given-Wilson,M Law,J Loughlin,Michael J Michell,Sue Moss,M Noblet,Julietta Patnick,Malcolm W.R. Reed,C Rubin,K Toward,D Winston,Joan Austoker,A Berrington,Roger G. Blanks,Nicholas E. Day,T J Day,Henrik Møller,M Quinn,Matthew G. Wallis,Wilson Arm.,Cancer Acb. +25 more
Reads0
Chats0
TLDR
Although some have questioned the value of screening for breast cancer, the scientific evidence demonstrates clearly that regular mammographic screening between the ages of 50 and 70 years reduces mortality from the malignancy.Abstract:
• The NHS Breast Screening Programme (NHSBSP) began in 1988. It aims to invite all women aged 50–70 years for mammographic screening once every three years. The programme now screens 1.3 million women each year, about 75% of those invited, and diagnoses about 10,000 breast cancers annually. • Although some have questioned the value of screening for breast cancer, the scientific evidence demonstrates clearly that regular mammographic screening between the ages of 50 and 70 years reduces mortality from the malignancy. • Screened women are slightly more likely than unscreened women to be diagnosed with breast cancer. The cancers in screened women are smaller and are less likely to be treated with mastectomy than they would have been if diagnosed without screening. •For every 400 women screened regularly by the NHSBSP over a 10-year period, one woman fewer will die from breast cancer than would have died without screening. • The current NHSBSP saves an estimated 1400 lives each year in England. • The screening programme spends about £3000 for every year of life saved.read more
Citations
More filters
Journal ArticleDOI
The benefits and harms of breast cancer screening: an independent review
TL;DR: It is concluded that screening reduces breast cancer mortality but that some overdiagnosis occurs, and results from observational studies support the occurrence of over Diagnosis, but estimates of its magnitude are unreliable.
Journal ArticleDOI
The benefits and harms of breast cancer screening: an independent review
TL;DR: The authors of as discussed by the authors reviewed the evidence on benefits and harms of breast screening in the context of the UK breast cancer screening programs and concluded that a 20% reduction is still the most reasonable estimate of the effect of the current UK screening programmes on breast cancer mortality.
Journal ArticleDOI
Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends
TL;DR: One in three breast cancers detected in a population offered organised screening is overdiagnosed, with data from three countries showing a drop in incidence as the women exceeded the age limit for screening, but the reduction was small.
Journal Article
Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Commentary
Benjamin Djulbeqovic,Gary H. Lyman,Sue Moss,Howard Cuckle,Andrew Evans,Louise Johns,Michael Waller,Lynda Bobrow +7 more
TL;DR: Although the reduction in breast-cancer mortality observed in this trial is not significant, it is consistent with results of other trials of mammography alone in this age-group and should take account of possible costs and harms as well as benefits.
Journal ArticleDOI
Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial
TL;DR: In this paper, the intention-to-treat principle was used to compare mortality rates in the two groups at 10 years' follow-up and the results showed a reduction in breast cancer mortality in the intervention group in relative and absolute terms.
References
More filters
Journal ArticleDOI
Breast cancer and hormone-replacement therapy in the Million Women Study.
TL;DR: Current use of HRT is associated with an increased risk of incident and fatal breast cancer; the effect is substantially greater for oestrogen-progestagen combinations than for other types of H RT.
Journal ArticleDOI
REDUCTION IN MORTALITY FROM BREAST CANCER AFTER MASS SCREENING WITH MAMMOGRAPHY: Randomised Trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare
Laszlo Tabar,Laszlo Tabar,Laszlo Tabar,Adel Gad,Adel Gad,Adel Gad,L. H. Holmberg,L. H. Holmberg,L. H. Holmberg,U. Ljungquist,U. Ljungquist,U. Ljungquist,C.J.G Fagerberg,C.J.G Fagerberg,C.J.G Fagerberg,L. Baldetorp,L. Baldetorp,L. Baldetorp,O Gröntoft,O Gröntoft,O Gröntoft,B. Lundström,B. Lundström,B. Lundström,J. C. Månson,J. C. Månson,J. C. Månson,Gunnar Eklund,Gunnar Eklund,Gunnar Eklund,N.E Day,N.E Day,N.E Day,F. Pettersson,F. Pettersson,F. Pettersson +35 more
TL;DR: 7 years after the start of the study the excess of stage I cancers in the study group largely outweighs the deficit of advanced cancers, and the results to the end of 1984 show a 31% reduction in mortality from breast cancer and a 25% reduced in the rate of stage II or more advanced breast cancers.
Journal ArticleDOI
Screening for breast cancer with mammography.
TL;DR: It is found that breast cancer mortality was an unreliable outcome that was biased in favour of screening, mainly because of differential misclassification of cause of death.
Journal ArticleDOI
Comparison of the Performance of Screening Mammography, Physical Examination, and Breast US and Evaluation of Factors that Influence Them: An Analysis of 27,825 Patient Evaluations
TL;DR: Mammographic sensitivity for breast cancer declines significantly with increasing breast density and is independently higher in older women with dense breasts, which significantly increases detection of small cancers and depicts significantly more cancers and at smaller size and lower stage than does PE, which detects independently extremely few cancers.
Journal ArticleDOI
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
Mieke Kriege,Cecile T. M. Brekelmans,Carla Boetes,Peter E. Besnard,H. M. Zonderland,Inge Marie Obdeijn,Radu A. Manoliu,Theo Kok,Hans Peterse,Madeleine M.A. Tilanus-Linthorst,Sara H. Muller,Sybren L. Meijer,Jan C. Oosterwijk,Louk V.A.M. Beex,Rob A. E. M. Tollenaar,Harry J. de Koning,Emiel J. Th. Rutgers,Jan G. M. Klijn +17 more
TL;DR: MRI appears to be more sensitive than mammography in detecting tumors in women with an inherited susceptibility to breast cancer.